Why Product Information Controls Matter for GDP Compliance
The MHRA has published a Drug Safety Update about finasteride and dutasteride, confirming updated warnings around psychiatric side effects and sexual dysfunction. The update explains that product information for medicines containing finasteride and dutasteride is being updated to provide more information on these side effects.
For healthcare professionals and patients, this is a medicine safety communication.
For medicines wholesale businesses, it is also a reminder that product information control matters.
A medicine is not only the physical product. The information around the product also matters.
What Happened and Why It Matters
The MHRA said it reviewed evidence relating to finasteride and dutasteride and the risk of suicidal thoughts and behaviours. It recommended further measures to minimise this risk.
The update also explains that patient cards for finasteride were introduced in 2024 and highlight risks around psychiatric and sexual side effects. Healthcare professionals are advised to inform patients of risks and to ask patients to read the patient cards and patient leaflet where relevant.
This matters because safety information can change.
When it changes, businesses in the wider medicines supply chain need to make sure their systems are capable of receiving, recording and acting on important updates.
What This Means for Medicines Wholesale Businesses
For medicines wholesale businesses, product information updates may not always feel like a direct operational issue.
But they can affect quality systems, documentation, communication and oversight.
A business should be able to answer:
- Who receives safety updates?
- Who reviews whether the update affects products or customers?
- Who tells the Responsible Person?
- Who checks whether supplier information has changed?
- Who records the review?
- Who communicates with customers where needed?
- Who updates SOPs or internal guidance if required?
- Who checks whether staff understand the change?
If those answers are unclear, the quality system may not be strong enough.
Why Product Information Controls Matter
Product information controls are part of a wider quality mindset.
They help ensure that important changes are not missed, ignored or handled informally.
Weak controls can create risk, such as:
- Safety updates not being reviewed
- Product information changes not being recorded
- Customer communication being inconsistent
- Staff using outdated information
- The Responsible Person not being sighted
- SOPs no longer reflecting current expectations
- Supplier communications being missed
- Records not showing what action was taken
These gaps may not appear serious at first.
But over time, they can weaken confidence in the quality system.
Why This Links to Responsible Person Oversight
The Responsible Person should have visibility over GDP quality risks that may affect the business.
That includes product information changes, safety communications, supplier notices, customer communications, recalls, defects and escalation processes.
The Responsible Person does not need to personally carry out every task.
But the business should have a clear system so the right information reaches the right person at the right time.
That is what good oversight looks like.
What Businesses Should Check Now
If your business is involved in medicines wholesale, WDA(H) readiness, specialist distribution or ongoing GDP compliance, this is a good time to review how product information updates are handled.
Start with these checks:
- Review who receives MHRA safety updates.
- Check how supplier communications are logged.
- Review whether product information changes are escalated to the right person.
- Check whether the Responsible Person has clear visibility.
- Review whether customer communication routes are documented.
- Check whether SOPs explain what happens when safety information changes.
- Review whether staff know how to handle product information updates.
- Check whether records show what was reviewed and what action was taken.
- Review whether Yellow Card reporting awareness is included where relevant.
- Check whether your system is practical in real life, not just written down.
- These checks are not about adding unnecessary admin.
They are about making sure important information is controlled, visible and acted on properly.
How Stag Global Helps
Stag Global does not supply medicines or products.
We support businesses with compliance-led review and readiness support.
This may include:
- Responsible Person / GDP quality support
- GDP audit and readiness support
- Product information control review
- SOP and documentation review
- Supplier and customer communication review
- Compliance route reviews
- WDA(H) application readiness
- Ongoing compliance support
- Inspection readiness support
Our role is to help businesses understand whether their systems are clear, practical and strong enough before risk becomes a bigger problem.
We help clients move forward with clarity, control and confidence.
Final Thought
A safety update may look like a communication issue.
But for regulated businesses, it is also a systems issue.
The key question is simple:
Can your business receive, review, record and act on important product information updates in a controlled way?
If the answer is unclear, now is the time to review your GDP quality system.
Need clarity on your product information controls, Responsible Person oversight or GDP quality systems?
Book a confidential consultation with Stag Global to review your compliance position before small gaps become bigger risks.
